Literature DB >> 8527505

Relaxin stimulates interstitial collagenase activity in cultured uterine cervical cells from nonpregnant and pregnant but not immature guinea pigs; estradiol-17 beta restores relaxin's effect in immature cervical cells.

T I Mushayandebvu1, M R Rajabi.   

Abstract

Relaxin has been implicated in dilatation of the cervix at parturition. Dilatation of the guinea pig cervix at parturition is mediated by an estrogen-induced degradation of type I collagen by interstitial collagenase (matrix metalloproteinase I, MMPI). This study was designed to test the hypothesis that human recombinant relaxin (hrR) stimulates MMPI activity in cultured guinea pig cervical cells. Primary cervical monolayer cultures from immature, adult nonpregnant, and 50-day-pregnant Hartley guinea pigs were exposed to hrR (1-1000 ng/ml) daily for 3 days in serum-free Dulbecco's Modified Eagle's Medium (DMEM). The effect of priming immature cells with estradiol-17 beta (E2, 10(-6) M) daily for 3 days prior to treatment with hrR was also determined. Tissue inhibitors of metalloproteinases were inactivated by reduction, alkylation, and dialysis. MMPI activity at 96 h was assayed via a highly sensitive and specific assay that utilizes [3H]telopeptide-free type I collagen as a substrate. Aminophenylmercuric acetate (0.5 mM) was used to activate latent MMPI. Phenanthroline-1,10 (1 mM), a known inhibitor of metalloproteinases, was used as a blank control. Phorbol-12-myristate-13-acetate (PMA, 10(-8) M), a known stimulator of MMPI biosynthesis, was used as a positive control. The hrR in serum-free DMEM had no significant effect on cell number in nonpregnant, 50-day-pregnant, E2-primed, or nonprimed immature animals. It stimulated MMPI activity in a dose-dependent manner with a maximum response at 10 ng/ml in nonpregnant (2-fold), 50-day-pregnant (3-fold), and E2-primed immature (3-fold) animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527505     DOI: 10.1095/biolreprod53.5.1030

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  7 in total

Review 1.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

2.  Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.

Authors:  E N Unemori; L B Pickford; A L Salles; C E Piercy; B H Grove; M E Erikson; E P Amento
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

3.  Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways.

Authors:  Nisar Ahmad; Wei Wang; Remi Nair; Sunil Kapila
Journal:  Mol Cell Endocrinol       Date:  2012-07-24       Impact factor: 4.102

4.  Female hormone receptors are differentially expressed in mouse fibrocartilages.

Authors:  W Wang; T Hayami; S Kapila
Journal:  Osteoarthritis Cartilage       Date:  2008-10-17       Impact factor: 6.576

5.  Matrix metalloproteinase induction by relaxin causes cartilage matrix degradation in target synovial joints.

Authors:  Sunil Kapila; Wei Wang; Karen Uston
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

6.  Relaxin and beta-estradiol modulate targeted matrix degradation in specific synovial joint fibrocartilages: progesterone prevents matrix loss.

Authors:  Gihan Hashem; Qin Zhang; Takayuki Hayami; Jean Chen; Wei Wang; Sunil Kapila
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Relaxin's induction of metalloproteinases is associated with the loss of collagen and glycosaminoglycans in synovial joint fibrocartilaginous explants.

Authors:  Tabassum Naqvi; Trang T Duong; Gihan Hashem; Momotoshi Shiga; Qin Zhang; Sunil Kapila
Journal:  Arthritis Res Ther       Date:  2004-10-29       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.